Lupin Ltd News

Lupin gets tentative nod from USFDA for generic Sugammadex injection

Pharma major Lupin Ltd on Tuesday said it has received tentative approval from the US health regulator for its generic version of Sugammadex injection used for reversing the effects of muscle relaxants given during surgery. The tentative approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Sugammadex Injection of strengths 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial, Lupin said in a regulatory filing. The USFDA has tentatively approved Lupin's Sugammadex injection of the specified strengths as bioequivalent to Merck's Bridion injection, it added. It is used for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery, the company said.

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Lupin, Zydus partner to co-market semaglutide injection in India

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity

Zydus, Lupin sign deal to co-market Semaglutide injections in India

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite

Lupin eyes next US growth pillar in complex generics and biosimilars

Nearly six decades after its founding, Lupin is targeting its next global growth phase in the US with a strategy centred on complex generics, biosimilars and innovation

Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%

In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.

Lupin rallies 12% thus far in CY26, outperforms market; here's why

In the past one month, Lupin has outperformed the market by soaring 6 per cent, as against 4.5 per cent decline in the BSE Sensex.

Further consolidation ahead for Nifty? Here's today's outlook and top picks

Ajit Mishra of Religare Broking has recommended buying the shares of Coal India, Hindustan Unilever, and Lupin today

Stocks to Watch today: Defence, OMCs, Aurobindo, GAIL, Lupin, NCC, HG Infra

Stocks to Watch today: Aurobindo Pharma, GAIL India, Lupin, NCC, HG Infra, Brigade Enterprises and Anupam Rasayan are among the stocks to watch today, March 02, 2026

Nifty Pharma index soars 7% thus far in February; nears 52-week high

Thus far in the month of February 2026, Laurus Labs surged 13%, while Sun Pharmaceutical Industries and Torrent Pharmaceuticals soared 11% each.

Maharashtra GST Department initiates inspection, search at Lupin office

Pharmaceuticals firm Lupin Ltd on Wednesday said Maharashtra GST Department has initiated inspection and search at its registered office in Mumbai. The inspection and search by the department seeking documents related to payment of GST and claim of input tax credit etc started at 11.50 am on February 25, 2026, Lupin said in a regulatory filing. The company is extending its cooperation with the officials and providing necessary information and documents, it added. The initiation of this inspection and search doesn't have any impact on the company's financials, operations or other activities, Lupin said.

Lupin gains 2%, hits 52-week high; why pharma stock in focus?

Lupin management remains confident that the India formulations business will continue to outperform IPM by 1.2-1.3 times, supported by strong sales force and pipeline of new product launches.

Stocks to Watch today, Feb 25: RIL, Schaeffler, Aditya Infotech, Hindalco

Stocks to Watch today, February 25, 2026: Schaeffler India, Aditya Infotech, RVL are among few stocks that will be in focus

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Stocks to Watch today, Feb 17: Cochin Shipyard, JSW Infra, Lupin, Seamec

Stocks to watch on February 17, 2026: Stocks like Cochin Shipyard, JSW Infrastructure, Lupin, TVS Supply Chain, and Seamec will remain in focus today

Stocks to buy today: Analyst at Kotak Sec bets on ICICI Bank, Lupin

Stocks to buy today: Shrikant Chouhan of Kotak Securities suggests placing bets on ICICI Bank and Lupin; here's why

Lupin rises post-Q3 analysts call, but brokerages flag FY27 earnings risk

In the December quarter, the company reported a 37 per cent growth in consolidated net profit at ₹1,175.5 crore, as compared to ₹855.16 crore a year ago

Stocks to Watch today: Bharti Airtel, LIC, Trent, NSDL, Tata Power, Marico

Stocks to Watch today, February 5, 2026: Medanta, JSW Cement, Cummins India, Emcure Pharma, Bajaj Finserv, Metropolis, Emami, Lupin, and NHPC are among the top stocks to watch today

Lupin, Biocon: Nifty Pharma gains 3% after US-India trade deal pact

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market,